검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells) Miltenyi Biomedicine GmbH·Metastatic Malignant Solid Neoplas… ORR 32% |
|---|---|
Overview Program | T-cell Receptor-engineered T-cells |
Overview Company | Miltenyi Biomedicine GmbH |
Overview Modality | CGT |
Overview Target | Metastatic Malignant Solid Neoplasm |
Overview Indication | Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Toxicology Major finding | How can we balance risk and benefit of interleukin-18 armored T cell therapies?. CD19-specific CAR T cells engineered to secrete a constitutively active form of the pro-inflammatory cytokine, interleukin (IL)-18 have demonstrated impressive efficacy in a recent clinical trial involving subjects who had failed prior CAR T cell therapy. Corroborating these clinical data, preclinical studies of IL-18… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 32% |
Clinical ORR | 32% |
Clinical Result source | ClinicalTrials.gov NCT01865617 |
Clinical Data Tier / Score | A · 21 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells) Miltenyi Biomedicine GmbH·Metastatic Malignant Solid Neoplas… ORR 32% |
|---|---|
Overview Program | T-cell Receptor-engineered T-cells |
Overview Company | Miltenyi Biomedicine GmbH |
Overview Modality | CGT |
Overview Target | Metastatic Malignant Solid Neoplasm |
Overview Indication | Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Toxicology Major finding | How can we balance risk and benefit of interleukin-18 armored T cell therapies?. CD19-specific CAR T cells engineered to secrete a constitutively active form of the pro-inflammatory cytokine, interleukin (IL)-18 have demonstrated impressive efficacy in a recent clinical trial involving subjects who had failed prior CAR T cell therapy. Corroborating these clinical data, preclinical studies of IL-18… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 32% |
Clinical ORR | 32% |
Clinical Result source | ClinicalTrials.gov NCT01865617 |
Clinical Data Tier / Score | A · 21 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
추천 비교
추천 비교